NASDAQ:ALLKAllakos Stock Price, Forecast & News

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALLK shares have increased by 36.4% and is now trading at $79.55.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Allakos.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020.
View our earnings forecast for Allakos.

Allakos Inc (NASDAQ:ALLK) issued its earnings results on Monday, May, 11th. The company reported ($0.57) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.01.
View Allakos' earnings history.

3 equities research analysts have issued twelve-month target prices for Allakos' shares. Their forecasts range from $36.00 to $94.00. On average, they expect Allakos' stock price to reach $65.00 in the next twelve months. This suggests that the stock has a possible downside of 18.3%.
View analysts' price targets for Allakos.

News stories about ALLK stock have been trending somewhat positive on Monday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allakos earned a news impact score of 1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Allakos.

Some companies that are related to Allakos include Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Bausch Health Companies (BHC) and ACADIA Pharmaceuticals (ACAD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Ascendis Pharma A/S (ASND) and Autolus Therapeutics (AUTL).

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.23%), SG Americas Securities LLC (0.04%), Mackay Shields LLC (0.04%), Dupont Capital Management Corp (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.00%) and UBS Group AG (0.00%). Company insiders that own Allakos stock include Guy P Nohra, John P Mckearn and Venture Fund (Ohi Rivervest II.
View institutional ownership trends for Allakos.

ALLK stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Allakos company stock in the last year include Guy P Nohra, and John P Mckearn.
View insider buying and selling activity for Allakos.

ALLK stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., SG Americas Securities LLC, Dupont Capital Management Corp, Mackay Shields LLC, UBS Group AG, Zurcher Kantonalbank Zurich Cantonalbank , and Strs Ohio.
View insider buying and selling activity for Allakos.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLK stock can currently be purchased for approximately $79.55.

Allakos has a market capitalization of $3.88 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe.

The official website for Allakos is www.allakos.com.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]